Nitric oxide synthase gene therapy - Cardion/Valentis

Drug Profile

Nitric oxide synthase gene therapy - Cardion/Valentis

Alternative Names: iNOS gene therapy - Cardion/Valentis; NOStentin

Latest Information Update: 16 Oct 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cardion; Valentis
  • Class Gene therapies
  • Mechanism of Action Nitric oxide synthase stimulants; Nitric oxide synthase type II modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Vascular restenosis

Most Recent Events

  • 08 May 2001 Phase-I clinical trials for Vascular restenosis in USA (Unknown route)
  • 27 Nov 2000 Cardiogene has merged with Intracardia to form Cardion
  • 25 Jan 2000 Preclinical development for Vascular restenosis in Germany (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top